| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human LIX1L recombinant protein (Position: L77-H333) was used as the immunogen for the LIX1L antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
LIX1L Antibody / Limb and CNS expressed protein 1-like is a anti-LIX1L Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as ELISA, Flow cytometry (FACS), Western blot (WB) with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: LIX1L
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): ELISA, FACS, WB
Biological background
LIX1L is expressed in several tissues, including the brain, liver, lung, and kidney, with enriched expression in mesenchymal and epithelial cell types. Studies suggest that LIX1L contributes to cell motility by influencing actin filament organization and adhesion dynamics. In hepatic tissue, it may participate in regeneration and fibrotic remodeling, while in the nervous system it supports neuronal morphogenesis. The protein is also expressed during embryogenesis, where it may cooperate with LIM-homeodomain transcription factors to guide organogenesis. Dysregulated expression of LIX1L has been associated with certain cancers, including hepatocellular carcinoma and glioma, where it correlates with invasive behavior and poor prognosis.
The LIX1L antibody is useful in developmental, cancer, and cytoskeletal research. Western blot analysis reveals a 35 kilodalton band corresponding to the full-length protein, and immunofluorescence shows cytoplasmic staining that co-localizes with filamentous actin structures. In cell migration assays, modulation of LIX1L levels alters lamellipodia formation and motility, highlighting its cytoskeletal role. Researchers use the LIX1L antibody to characterize its distribution across tissues and to evaluate its potential as a biomarker of epithelial plasticity.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
